Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment

References

• Jewell AP, Lydyard PM, Worman CP, et al. Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without stimulating proliferation. Leuk Lymphoma. 1995;18:159–162.
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114:4441–4450.
   PubMed Web of Science ®Google Scholar
• Vogler M, Butterworth M, Majid A, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113:4403–4413.
   PubMed Web of Science ®Google Scholar
• Burger JA. The CLL cell microenvironment. Adv Exp Med Biol. 2013;792:25–45.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (Imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P T. 2014;39:483–519.
   PubMedGoogle Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia . Blood. 2014;123:3390–3397.
   PubMed Web of Science ®Google Scholar
• Balakrishnan K, Peluso M, Fu M, et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015;29:1811–1822.
   PubMed Web of Science ®Google Scholar
• ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia–focus on the B-cell receptor. Clin Cancer Res. 2014;20:548–556.
   PubMed Web of Science ®Google Scholar
• Maffei R, Fiorcari S, Martinelli S, et al. Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib. J Hematol Oncol. 2015;8:60.
   PubMed Web of Science ®Google Scholar
• Herman SE, Mustafa RZ, Jones J, et al. Treatment with Ibrutinib Inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo. Clin Cancer Res. 2015;21:4642–4651.
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591–594.
   PubMed Web of Science ®Google Scholar
• Shen Y, Best OG, Mulligan SP, et al. Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment. Leuk Lymphoma. 2018;59:1927–1937.
   PubMed Web of Science ®Google Scholar
• Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182–1189.
   PubMed Web of Science ®Google Scholar
• Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802:396–405.
   PubMed Web of Science ®Google Scholar
• Steelman LS, Franklin RA, Abrams SL, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 2011;25:1080–1094.
   PubMed Web of Science ®Google Scholar
• Messmer D, Fecteau JF, O’Hayre M, et al. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood. 2011;117:882–889.
   PubMed Web of Science ®Google Scholar
• Crassini K, Shen YD, Stevenson WS, et al. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. Br J Haematol. 2018;182:360–372.
   PubMed Web of Science ®Google Scholar
• Ding W, Shanafelt TD, Lesnick CE, et al. Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. Br J Haematol. 2014;164:146–150.
   PubMed Web of Science ®Google Scholar
• Yap TA, Yan L, Patnaik A, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011;29:4688–4695.
   PubMed Web of Science ®Google Scholar
• Larsen JT, Shanafelt TD, Leis JF, et al. Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: results from the N1087 alliance study. Am J Hematol. 2017;92:759–763.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Best OG, Gardiner AC, Majid A, et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia. 2008;22:1456–1459.
   PubMed Web of Science ®Google Scholar
• Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363:105–111.
   PubMed Web of Science ®Google Scholar
• Hertlein E, Beckwith KA, Lozanski G, et al. Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. PLoS One. 2013;8:e76607.
   PubMed Web of Science ®Google Scholar
• Crassini K, Stevenson WS, Mulligan SP, et al. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. Leuk Lymphoma. 2015;56:3407–3417.
   PubMed Web of Science ®Google Scholar
• Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3:e00149.
   PubMed Web of Science ®Google Scholar
• Barragan M, de Frias M, Iglesias-Serret D, et al. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}. J Leukoc Biol. 2006;80:1473–1479.
   PubMed Web of Science ®Google Scholar
• Robert G, Ben Sahra I, Puissant A, et al. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PLoS One. 2009;4:e7889.
   PubMed Web of Science ®Google Scholar
• Chen CH, Hsia TC, Yeh MH, et al. MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701. Mol Oncol. 2017;11:1273–1287.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
   PubMed Web of Science ®Google Scholar
• Coutre SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779–2786.
   PubMed Web of Science ®Google Scholar
• Jin F, Robeson M, Zhou H, et al. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. J Clin Pharmacol. 2015;55:944–952.
   PubMed Web of Science ®Google Scholar
• Paul J, Soujon M, Wengner AM, et al. Simultaneous inhibition of PI3Kdelta and PI3Kalpha induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-kappaB and AKT. Cancer Cell. 2017;31:64–78.
   PubMed Web of Science ®Google Scholar
• Majewski M, Nieborowska-Skorska M, Salomoni P, et al. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res. 1999;59:2815–2819.
   PubMed Web of Science ®Google Scholar
• Castellano E, Molina-Arcas M, Krygowska AA, et al. RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression. Nat Commun. 2016;7:11245.
   PubMed Web of Science ®Google Scholar
• Molina-Arcas M, Hancock DC, Sheridan C, et al. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov. 2013;3:548–563.
   PubMed Web of Science ®Google Scholar
• Saisana M, Griffin SM, May FE. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. Oncotarget. 2016;7:54445–54462.
   PubMedGoogle Scholar
• Cao Z, Liu LZ, Dixon DA, et al. Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell Signal. 2007;19:1542–1553.
   PubMed Web of Science ®Google Scholar
• Coco S, Truini A, Alama A, et al. Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. Targ Oncol. 2015;10:393–404.
   PubMed Web of Science ®Google Scholar
• Barragan M, Bellosillo B, Campas C, et al. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood. 2002;99:2969–2976.
   PubMed Web of Science ®Google Scholar
• Alkan S, Huang Q, Ergin M, et al. Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition. Am J Hematol. 2005;79:97–106.
   PubMed Web of Science ®Google Scholar
• Wang B, Shi L, Sun X, et al. Production of CCL20 from lung cancer cells induces the cell migration and proliferation through PI3K pathway. J Cell Mol Med. 2016;20:920–929.
   PubMed Web of Science ®Google Scholar
• Yang X, Wang J, Liu S, et al. HSF1 and Sp1 regulate FUT4 gene expression and cell proliferation in breast cancer cells. J Cell Biochem. 2014;115:168–178.
   PubMed Web of Science ®Google Scholar
• Lim W, Jeong W, Song G. Delphinidin suppresses proliferation and migration of human ovarian clear cell carcinoma cells through blocking AKT and ERK1/2 MAPK signaling pathways. Mol Cell Endocrinol. 2016;422:172–181.
   PubMed Web of Science ®Google Scholar
• Longo PG, Laurenti L, Gobessi S, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 2007;21:110–120.
   PubMed Web of Science ®Google Scholar
• Calvo N, Martin MJ, de Boland AR, et al. Involvement of ERK1/2, p38 MAPK, and PI3K/Akt signaling pathways in the regulation of cell cycle progression by PTHrP in colon adenocarcinoma cells. Biochem Cell Biol. 2014;92:305–315.
   PubMed Web of Science ®Google Scholar
• Hong J, Qian T, Le Q, et al. NGF promotes cell cycle progression by regulating D-type cyclins via PI3K/Akt and MAPK/Erk activation in human corneal epithelial cells. Mol Vis. 2012;18:758–764.
   PubMed Web of Science ®Google Scholar
• Lavoie JN, L’Allemain G, Brunet A, et al. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem. 1996;271:20608–20616.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203.
   PubMed Web of Science ®Google Scholar